Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joohyuk Sohn

Showing results (31-40 of 130) with videos related to

Pageof 13
Sort By:
Future Oncology (London, England)|April 1, 2020
TROPiCS-02: A Phase III study investigating sacituzumab govitecan in the treatment of HR+/HER2- metastatic breast cancerHope S Rugo, Aditya Bardia, Sara M Tolaney, et al.
The Oncologist|February 12, 2020
Health-Related Quality of Life in MONARCH 2: Abemaciclib plus Fulvestrant in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer After Endocrine TherapyPeter A Kaufman, Masakazu Toi, Patrick Neven, et al.
Yonsei Medical Journal|November 23, 2016
Detection of Circulating Tumor Cells in Breast Cancer Patients Using Cytokeratin-19 Real-Time RT-PCRHyung Seok Park, Hyun Ju Han, Soohyeon Lee, et al.
Breast Cancer Research and Treatment|December 8, 2019
Intermediate HER2 expression is associated with poor prognosis in estrogen receptor-positive breast cancer patients aged 55 years and olderMin Hwan Kim, Gun Min Kim, Jee Hung Kim, et al.
Journal of Breast Cancer|April 12, 2016
Incidence of Febrile Neutropenia in Korean Female Breast Cancer Patients Receiving Preoperative or Postoperative Doxorubicin/Cyclophosphamide Followed by Docetaxel ChemotherapyChang Gon Kim, Joohyuk Sohn, Hongjae Chon, et al.
Journal of Experimental & Clinical Cancer Research : CR|November 29, 2023
Targeting PEG10 as a novel therapeutic approach to overcome CDK4/6 inhibitor resistance in breast cancerNar Bahadur Katuwal, Min Sil Kang, Mithun Ghosh, et al.
Experimental & Molecular Medicine|April 15, 2024
Overcoming BRAF and CDK4/6 inhibitor resistance by inhibiting MAP3K3-dependent protection against YAP lysosomal degradationSanghyun Park, Won-Ji Ryu, Tae Yeong Kim, et al.
BMC Cancer|December 10, 2013
S-1 combined with docetaxel following doxorubicin plus cyclophosphamide as neoadjuvant therapy in breast cancer: phase II trialYong Wha Moon, Soohyeon Lee, Byeong-Woo Park, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2022
Clinical Significance of PIK3CA and ESR1 Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus FulvestrantSara M Tolaney, Masakazu Toi, Patrick Neven, et al.
Annals of Surgical Treatment and Research|May 9, 2017
Next-generation sequencing of <i>BRCA1/2</i> in breast cancer patients: potential effects on clinical decision-making using rapid, high-accuracy genetic resultsHyung Seok Park, Seo-Jin Park, Jee Ye Kim, et al.
Pageof 13

Showing results (31-40 of 130) with videos related to

Sort By:
Pageof 13
Future Oncology (London, England)|April 1, 2020
TROPiCS-02: A Phase III study investigating sacituzumab govitecan in the treatment of HR+/HER2- metastatic breast cancerHope S Rugo, Aditya Bardia, Sara M Tolaney, et al.
The Oncologist|February 12, 2020
Health-Related Quality of Life in MONARCH 2: Abemaciclib plus Fulvestrant in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer After Endocrine TherapyPeter A Kaufman, Masakazu Toi, Patrick Neven, et al.
Yonsei Medical Journal|November 23, 2016
Detection of Circulating Tumor Cells in Breast Cancer Patients Using Cytokeratin-19 Real-Time RT-PCRHyung Seok Park, Hyun Ju Han, Soohyeon Lee, et al.
Breast Cancer Research and Treatment|December 8, 2019
Intermediate HER2 expression is associated with poor prognosis in estrogen receptor-positive breast cancer patients aged 55 years and olderMin Hwan Kim, Gun Min Kim, Jee Hung Kim, et al.
Journal of Breast Cancer|April 12, 2016
Incidence of Febrile Neutropenia in Korean Female Breast Cancer Patients Receiving Preoperative or Postoperative Doxorubicin/Cyclophosphamide Followed by Docetaxel ChemotherapyChang Gon Kim, Joohyuk Sohn, Hongjae Chon, et al.
Journal of Experimental & Clinical Cancer Research : CR|November 29, 2023
Targeting PEG10 as a novel therapeutic approach to overcome CDK4/6 inhibitor resistance in breast cancerNar Bahadur Katuwal, Min Sil Kang, Mithun Ghosh, et al.
Experimental & Molecular Medicine|April 15, 2024
Overcoming BRAF and CDK4/6 inhibitor resistance by inhibiting MAP3K3-dependent protection against YAP lysosomal degradationSanghyun Park, Won-Ji Ryu, Tae Yeong Kim, et al.
BMC Cancer|December 10, 2013
S-1 combined with docetaxel following doxorubicin plus cyclophosphamide as neoadjuvant therapy in breast cancer: phase II trialYong Wha Moon, Soohyeon Lee, Byeong-Woo Park, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2022
Clinical Significance of PIK3CA and ESR1 Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus FulvestrantSara M Tolaney, Masakazu Toi, Patrick Neven, et al.
Annals of Surgical Treatment and Research|May 9, 2017
Next-generation sequencing of <i>BRCA1/2</i> in breast cancer patients: potential effects on clinical decision-making using rapid, high-accuracy genetic resultsHyung Seok Park, Seo-Jin Park, Jee Ye Kim, et al.
Pageof 13